Allurion Technologies Holdings Inc. has announced findings from two new studies presented at the 2025 Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS). These studies reinforce the efficacy of the Allurion Program, which combines a procedure-less gastric balloon, AI-powered remote support, and real-time digital monitoring, in achieving metabolically healthy weight loss. The data, drawn from nearly 20,000 patients, demonstrate significant fat loss and preservation of muscle mass. Additionally, in one of the longest real-world studies of its kind, patients maintained, on average, 89% of the weight lost during balloon therapy over four years. These results contribute to Allurion's evidence base as the company prepares to complete its FDA submission.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。